CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth

Cancer Research

Volumn 72, Issue 14, 2012, Pages 3664-3676

  Claus, Christina ^a   Riether, Carsten ^a   Schürch, Christian ^a   Matter, Matthias S ^a   Hilmenyuk, Tamara ^a   Ochsenbein, Adrian F ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD70 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; IMMUNOCOMPETENCE; IMMUNOGENICITY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD27; ANTIGENS, CD70; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84863938832     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2791     Document Type: Article

References (56)

1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11. (Pubitemid 32391043)
2. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64. (Pubitemid 32612331)
3. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6. (Pubitemid 26391458)
4. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13. (Pubitemid 34087893)
5. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
6. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4+cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-91. (Pubitemid 40395122)
7. Bignone PA, BanhamAH. FOXP3+ regulatory T cells as biomarkers in human malignancies. Expert Opin Biol Ther 2008;8:1897-920.
8. Sakaguchi S. Naturally arising CD4+regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62. (Pubitemid 38680433)
9. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009;30:626-35.
10. Qin FX. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell Mol Immunol 2009;6:3-13.
11. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005;17:275-81. (Pubitemid 40692662)
12. Matter M, Mumprecht S, Pinschewer DD, Pavelic V, Yagita H, Krautwald S, et al. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. Eur J Immunol 2005;35:3229-39. (Pubitemid 41672527)
13. Peperzak V, Xiao Y, Veraar EA, Borst J. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest 2010;120:168-78.
14. Matter M, Odermatt B, Yagita H, Nuoffer JM, Ochsenbein AF. Elimination of chronic viral infection by blocking CD27 signaling. J Exp Med 2006;203:2145-55. (Pubitemid 44352235)
15. Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009;229:216-31.
16. Penaloza-MacMaster P, Ur Rasheed A, Iyer SS, Yagita H, Blazar BR, Ahmed R. Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice. J Virol 2011;85:6168-74.
17. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 2007;110:2537-44. (Pubitemid 47523176)
18. + T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788-801.
19. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002;62:2592-9. (Pubitemid 34462739)
20. Lorenz MG, Kantor JA, Schlom J, Hodge JW. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 1999;10:1095-103. (Pubitemid 29231854)
21. Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response. J Immunother 1998;21:225-36. (Pubitemid 28222281)
22. Aulwurm S, Wischhusen J, Friese M, Borst J, Weller M. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer 2006;118:1728-35. (Pubitemid 43376436)
23. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007;109:4810-5. (Pubitemid 46827776)
24. Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 2010;33:769-79.
25. Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+T cell formation. J Exp Med 2004;199:1595-605. (Pubitemid 38780414)
26. Keller AM, Schildknecht A, Xiao Y, van den Broek M, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 2008;29:934-46.
27. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006;66:2328-37.
28. Sloan DD, Nicholson B, Urquidi V, Goodison S. Detection of differentially expressed genes in an isogenic breast metastasis model using RNA arbitrarily primed-polymerase chain reaction coupled with array hybridization (RAP-array). Am J Pathol 2004;164:315-23. (Pubitemid 38364615)
29. Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001;61:2031-7. (Pubitemid 32692024)
30. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5. (Pubitemid 27264981)
31. Choi BK, Kim YH, Kim CH, Kim MS, Kim KH, Oh HS, et al. Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma. J Immunol 2010;185:1404-11.
32. Ehl S, Hombach J, Aichele P, Rulicke T, Odermatt B, Hengartner H, et al. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+T cells to cause immunopathology. J Exp Med 1998;187:763-74. (Pubitemid 28115192)
33. Schaefer BC, Schaefer ML, Kappler JW, Marrack P, Kedl RM. Observation of antigen-dependent CD8+ T-cell/dendritic cell interactions in vivo. Cell Immunol 2001;214:110-22. (Pubitemid 34499465)
34. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000;1:433-40.
35. Matter M, Pavelic V, Pinschewer DD, Mumprecht S, Eschli B, Giroglou T, et al. Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res 2007;67:7467-76. (Pubitemid 47206576)
36. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8. (Pubitemid 16119452)
37. Mumprecht S, Claus C, Schürch C, Pavelic V, Matter MS, Ochsenbein AF. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood 2009;113:4681-9.
38. Jakob S, Corazza N, Diamantis E, Kappeler A, Brunner T. Detection of apoptosis in vivo using antibodies against caspase-induced neoepitopes. Methods 2008;44:255-61. (Pubitemid 351296440)
39. van Olffen RW, Koning N, van Gisbergen KP, Wensveen FM, Hoek RM, Boon L, et al. GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol 2009;182:7490-500.
40. Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein AF. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest 2012;122:624-38.
41. Matter M, Pavelic V, Pinschewer DD, Mumprecht S, Eschli B, Giroglou T, et al. Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res 2007;67:7467-76. (Pubitemid 47206576)
42. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999;96:2233-8. (Pubitemid 29117897)
43. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43. (Pubitemid 43011261)
44. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-32. (Pubitemid 32983017)
45. Tesselaar K, Xiao Y, Arens R, van Schijndel GM, Schuurhuis DH, Mebius RE, et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003;170:33-40. (Pubitemid 36026120)
46. De Milito A, Aleman S, Marenzi R, Sonnerborg A, Fuchs D, Zazzi M, et al. Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. Clin Exp Immunol 2002;127:486-94. (Pubitemid 34437820)
47. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010;184:3433-41.
48. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-51. (Pubitemid 41541792)
49. Pandiyan P, Lenardo MJ. The control of CD4+CD25+Foxp3+ regulatory T cell survival. Biol Direct 2008;3:6.
50. Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005;201:1793-803. (Pubitemid 41002898)
51. Matter MS, Claus C, Ochsenbein AF. CD4+ T cell help improves CD8+ T cell memory by retained CD27 expression. Eur J Immunol 2008;38:1847-56.
52. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37. (Pubitemid 43053650)
53. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A 2007;104:19446-51.
54. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46. (Pubitemid 46009952)
55. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008;18:11-8. (Pubitemid 351694442)
56. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006;107:1018-23. (Pubitemid 43156300)